Browse News

Found 34 articles

• Microba Launches Next Generation Healthcare Testing

  2/28/2023

  Microba Life Sciences Limited, a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.

• Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners

  1/6/2023

  Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the opening of Bioworks7, the latest expansion of its biological engineering foundry.

• Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership

  11/29/2022

  Microba Life Sciences Limited is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba.

• SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

  10/27/2022

  SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

• Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools

  9/1/2022

  Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools.

• Microba Accelerates Cancer Program With New Leads

  5/5/2022

  Microba Life Sciences Limited is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected.

• 

  Global Roundup: Ginkgo/Microba Autoimmune Pact and New Parkinson's Data

  4/7/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics

  4/4/2022

  Microba Life Sciences, a precision microbiome science company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, announced a partnership to identify single-strain, live bacteria product candidates against autoimmune diseases.

• Arc Bio Joins Microbiome Therapeutics Innovation Group

  2/9/2022

  The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Arc Bio to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.

• Microba to Present Therapeutic Discovery Progress at Microbiome Movement – Drug Development Summit

  1/25/2022

  Microba Life Sciences, a precision microbiome science company, will showcase its Therapeutic Platform and Discovery Platform for the identification of novel microbial signatures at annual Europe summit.

• Research into gut microbiome-autism link reveals new perspective in collaborative Austism CRC study

  11/12/2021

  Results published in Cell, led by Mater Research and The University of Queensland, show that dietary restriction drives microbiome diversity changes in autistic individuals.

• International experts join Microba Life Sciences inaugural IBD Advisory Panel

  6/28/2021

  Precision microbiome science company, Microba Life Sciences, has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes for IBD sufferers.

• Microba Life Sciences and Illumina partner to accelerate microbiome research

  5/25/2021

  Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies to advance understanding of the human gut microbiome in human health and disease.

• Forensic DNA preservation method best for gut microbiome samples: Microba Life Sciences

  5/7/2021

  Microba Life Sciences, leaders in precision gut microbiome science, have demonstrated the superiority of their faecal sample preservation method against others, with a robust, peer-reviewed study published in ISME Communications.

• Genetic Analysis Joins Microbiome Therapeutics Innovation Group

  5/3/2021

  The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Norwegian molecular diagnostic company Genetic Analysis AS to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.

• Microba Life Sciences study shows Microba Community Profiler outperforms competition

  4/23/2021

  Leaders in precision gut microbiome science, Microba Life Sciences have demonstrated how their proprietary Microba Community Profiler compares to other metagenomic profilers, with the study published in Frontiers in Microbiology.

• Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group

  3/29/2021

  The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Australian Biotech company Servatus Biopharmaceuticals Ltd to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.

• Microba Life Sciences appoints experienced executive Mark Capone to the Board

  3/18/2021

  Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector.

• Microba Life Sciences partners with Unilever to target sleep through the gut microbiome

  3/15/2021

  The Centre for Disease Control and Prevention has declared insufficient sleep a 'public health problem', with more than one-third of American adults not getting enough sleep on a regular basis.

• Microba Life Sciences Joins Microbiome Therapeutics Innovation Group

  2/22/2021

  The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Microba Life Sciences to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products.